1700 Owens Street
Nurix, Inc. is a privately-held San Francisco-based biotechnology company that is focused on bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating the protein degradation of the cell. The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding the ubiquitin proteasome system (UPS). Nurix was founded by internationally-recognized experts in the UPS field and is funded by leading life sciences investors, Third Rock Ventures and The Column Group. In September 2015 Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly-evolving field of immune-oncology.